Non-Dilutive $1.5M Grant Fuels Aptevo's APVO451 Drug Development
APVO sits 17% above its 52-week low of $3.8 on elevated volume (3.5× avg).
Summary
Aptevo Therapeutics secured a $1.5 million non-dilutive grant from the Andy Hill CARE Fund to advance IND-enabling studies for its APVO451 trispecific antibody for solid tumors. This funding is highly material, representing approximately 27% of the company's current market capitalization. The grant provides crucial financial support for a key drug candidate without further diluting shareholders, which is particularly significant given the company's Q1 net loss and reiterated going concern warning in May. The project period runs through June 2028, with payments tied to milestones.
At the time of this announcement, APVO was trading at $4.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $3.80 to $59.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.